0

Close
 
Upcoming Allied Market Research
2023
Angiogenesis Inhibitor And Simulator Market

Angiogenesis Inhibitor and Simulator Market

by Product Type (Intussusceptive Angiogenesis  , Sprouting Angiogenesis) and by End User (Hospitals, Clinics, Others): Global Opportunity Analysis and Industry Forecast, 2023-2032

LS : Pharmaceuticals
Report Code: A12462
Nov 2023 | Pages: NA
Tables: NA
Charts: NA

  • Formats*:

  • pdf

    Single User License, Five User
    License & Enterprise User License

  • xls

    Data Pack Excel License

  • ppt

    It comes with the additional cost
    of $2500.00 contact sales.
 

COVID-19

Pandemic disrupted the entire world and affected many industries.

Get detailed COVID-19 impact analysis on the Angiogenesis Inhibitor And Simulator Market

Request Now !

Angiogenesis Inhibitor and Simulator Market Outlook 2030:

Angiogenesis is the process of formation or regeneration of new blood vessels out of older ones. It involves migration, differentiation, and subsequent growth of endothelial cells, which are present at the inner lining of blood vessels. The process is considered vital for growth and development of new skin post wound healing. Angiogenesis continues the process of growth of cells through constant sprouting and splitting. It is associated with cancer treatment, as it allows delivery of oxygen and other vital nutrients inside patient’s body. Cancer tumor requires oxygen and nutrients to survive and grow inside the body and thus angiogenesis inhibitors. Anti-angiogenics are drugs that block the nutrients from reach tumor site, thus starving it until its departure. Few of the commonly used anti-angiogenics are sunitinib, lenalidomide, and vandetanib. Angiogenesis can be stopped naturally through high intake of food items such as berries, soya chunks, garlic, and parsley.

Angiogenesis inhibitor and simulator market can be segmented based on type of product which includes sprouting angiogenesis involving formation of new blood vessels through local proliferation of endolethial cells from the inner wall of blood vessels. In this, the tip of endolethial cells respond to environmental cues and direct migration of adjacent cells. In contrast, under intussusceptive angiogenesis, the capillary wall extends deep inside lumen, thus splitting a single vessel into individual two. Additionally, angiogenesis simulation occurs through interaction with inflammatory cytokines, adhesion molecules, and nitrous oxide. The overall market is segmented depending on end user, with hospitals and clinics being the dominating the market, owing rise in sales of drugs in these settings.

COVID-19 Impact Analysis

Pharmaceutical and biotech companies together with governments around the globe are working to address the COVID-19 outbreak, from supporting the development of vaccines to planning for medicine supply chain challenges. Currently, around 115 vaccine candidates and 155 molecules are in the R&D pipeline. Moreover, commonly used drugs such as hydroxychloroquine have witnessed a dramatic surge in demand for the management of COVID-19. Such high demand for these drugs has presented huge opportunities for manufacturers of COVID-19 management drugs, as many developed countries are facing shortage of these drugs. Thus, the pharmaceutical and biotechnology industries are expected to witness a significant growth in the future, owing to the demand for vaccine and treatment drugs for COVID-19. This, in turn, is expected to have a significant impact on the angiogenesis inhibitor and simulator market.

Top Impacting Factors

  • Increase in prevalence of cancer case around the globe and subsequent need for development of treatment therapeutics are likely to drive the growth of angiogenesis inhibitor and simulator market.
  • Acceptance of oncology as the major treatment by medical professionals and policy makers is another factor anticipated to drive the angiogenesis inhibitor and simulator market growth.
  • Rise in research and development investments across subdomains under healthcare and drug delivery, owing to COVID-19 and shift toward epidemic-free world are likely to bring in more investments in the oncology and angiogenesis simulator market.
  • Enhancements in the possible benefits of angiogenesis inhibitors such as axitinib and cabozantinib is likely to garner trust of healthcare experts and drive the angiogenesis inhibitor and simulator market growth.
  • However, high treatment costs associated with oncology acts as a restraint in densely populated, low-income economies.
  • Additionally, rogue state policies and regulatory norms in communist nations such as Cuba and Vietnam is likely to hamper the idea of a global network outreach with respect to angiogenesis inhibitor and simulator market.

Key Market Trends

  • North America is anticipated to expect huge gains with respect to angiogenesis inhibitor and simulator market, owing to rapid increase in number of cancer cases and subsequent rise in demand for advanced therapeutic treatment.
  • Largest growth recipient for angiogenesis simulating products in the current scenario is the treatment of peripheral vascular disease and coronary artery disease. Under the scenario, GenVecs’s BioByPaass is the largest gene therapy selling drug.
  • India and China are anticipated to gain significant traction, owing to responsive government actions, emergence of new regional private players, and increased inter & intra state collaborations.

Key Benefits of the Report

  • This study presents the analytical depiction of the angiogenesis inhibitor and simulator industry along with the current trends and future estimations to determine the imminent investment pockets.
  • The report presents information related to key drivers, restraints, and opportunities along with a detailed analysis of the market share.
  • The current market is quantitatively analyzed to highlight the market growth scenario.
  • Porter’s five forces analysis illustrates the potency of buyers & suppliers in the market.
  • The report provides a detailed analysis depending on competitive intensity and how the competition will take shape in the coming years.

Questions Answered in the Angiogenesis Inhibitor and Simulator Report

  • Which are the leading players active in the angiogenesis inhibitor and simulator market?
  • How is each segment of the market expected to grow during the forecast period?
  • What are the adoption trends for the angiogenesis inhibitor and simulator market in emerging economies and established economies across the world?
  • What are the current trends that will influence the market in the next few years?
  • What are the driving factors, restraints, and opportunities of the market?
  • What future projections would help in taking further strategic steps?
  • What are the impacts of COVID-19 in the industry?
  • What is angiogenesis inhibitor and simulator?
  • What is the angiogenesis inhibitor and simulator market prediction in the future?
  • What are the current trends and predicted trends?

 Angiogenesis Inhibitor and Simulator Market Report Highlights

Aspects Details
By Product Type
  • Intussusceptive Angiogenesis  
  • Sprouting Angiogenesis
By End User
  • Hospitals
  • Clinics
  • Others
By Region
  • North America  (U.S., Canada, Mexico)
  • Europe  (France, Germany, Italy, Spain, UK, Rest of Europe)
  • Asia-Pacific  (China, Japan, India, South Korea, Australia, Rest of Asia-Pacific)
  • LAMEA  (Brazil, South Africa, Saudi Arabia, Rest of LAMEA)
Key Market Players CASI Pharmaceuticals Inc., AstraZeneca, Abbott, F. Hoffmann-La Roche Ltd, Bristol-Myers Squibb Company, Pfizer Inc., Novartis AG, EYETECH DIGITAL SYSTEMS, Johns Hopkins Medicine, Amgen Inc.,
 

  • CHAPTER 1: INTRODUCTION

    • 1.1. Report Description

    • 1.2. Key Market Segments

    • 1.3. Key Benefits

    • 1.4. Research Methodology

      • 1.4.1. Primary Research

      • 1.4.2. Secondary Research

      • 1.4.3. Analyst Tools and Models

  • CHAPTER 2: EXECUTIVE SUMMARY

    • 2.1. CXO Perspective

  • CHAPTER 3: MARKET LANDSCAPE

    • 3.1. Market Definition and Scope

    • 3.2. Key Findings

      • 3.2.1. Top Investment Pockets

      • 3.2.2. Top Winning Strategies

    • 3.3. Porter's Five Forces Analysis

      • 3.3.1. Bargaining Power of Suppliers

      • 3.3.2. Threat of New Entrants

      • 3.3.3. Threat of Substitutes

      • 3.3.4. Competitive Rivalry

      • 3.3.5. Bargaining Power among Buyers

    • 3.5. Market Dynamics

      • 3.5.1. Drivers

      • 3.5.2. Restraints

      • 3.5.3. Opportunities

    • 3.6. COVID-19 Impact Analysis

  • CHAPTER 4: ANGIOGENESIS INHIBITOR AND SIMULATOR MARKET, BY PRODUCT TYPE

    • 4.1. Market Overview

      • 4.1.1 Market Size and Forecast, By Product Type

    • 4.2. Intussusceptive Angiogenesis  

      • 4.2.1. Key Market Trends, Growth Factors and Opportunities

      • 4.2.2. Market Size and Forecast, By Region

      • 4.2.3. Market Share Analysis, By Country

    • 4.3. Sprouting Angiogenesis

      • 4.3.1. Key Market Trends, Growth Factors and Opportunities

      • 4.3.2. Market Size and Forecast, By Region

      • 4.3.3. Market Share Analysis, By Country

  • CHAPTER 5: ANGIOGENESIS INHIBITOR AND SIMULATOR MARKET, BY END USER

    • 5.1. Market Overview

      • 5.1.1 Market Size and Forecast, By End User

    • 5.2. Hospitals

      • 5.2.1. Key Market Trends, Growth Factors and Opportunities

      • 5.2.2. Market Size and Forecast, By Region

      • 5.2.3. Market Share Analysis, By Country

    • 5.3. Clinics

      • 5.3.1. Key Market Trends, Growth Factors and Opportunities

      • 5.3.2. Market Size and Forecast, By Region

      • 5.3.3. Market Share Analysis, By Country

    • 5.4. Others

      • 5.4.1. Key Market Trends, Growth Factors and Opportunities

      • 5.4.2. Market Size and Forecast, By Region

      • 5.4.3. Market Share Analysis, By Country

  • CHAPTER 6: ANGIOGENESIS INHIBITOR AND SIMULATOR MARKET, BY REGION

    • 6.1. Market Overview

      • 6.1.1 Market Size and Forecast, By Region

    • 6.2. North America

      • 6.2.1. Key Market Trends and Opportunities

      • 6.2.2. Market Size and Forecast, By Product Type

      • 6.2.3. Market Size and Forecast, By End User

      • 6.2.4. Market Size and Forecast, By Country

      • 6.2.5. U.S. Angiogenesis Inhibitor And Simulator Market

        • 6.2.5.1. Market Size and Forecast, By Product Type
        • 6.2.5.2. Market Size and Forecast, By End User

      • 6.2.6. Canada Angiogenesis Inhibitor And Simulator Market

        • 6.2.6.1. Market Size and Forecast, By Product Type
        • 6.2.6.2. Market Size and Forecast, By End User

      • 6.2.7. Mexico Angiogenesis Inhibitor And Simulator Market

        • 6.2.7.1. Market Size and Forecast, By Product Type
        • 6.2.7.2. Market Size and Forecast, By End User

    • 6.3. Europe

      • 6.3.1. Key Market Trends and Opportunities

      • 6.3.2. Market Size and Forecast, By Product Type

      • 6.3.3. Market Size and Forecast, By End User

      • 6.3.4. Market Size and Forecast, By Country

      • 6.3.5. France Angiogenesis Inhibitor And Simulator Market

        • 6.3.5.1. Market Size and Forecast, By Product Type
        • 6.3.5.2. Market Size and Forecast, By End User

      • 6.3.6. Germany Angiogenesis Inhibitor And Simulator Market

        • 6.3.6.1. Market Size and Forecast, By Product Type
        • 6.3.6.2. Market Size and Forecast, By End User

      • 6.3.7. Italy Angiogenesis Inhibitor And Simulator Market

        • 6.3.7.1. Market Size and Forecast, By Product Type
        • 6.3.7.2. Market Size and Forecast, By End User

      • 6.3.8. Spain Angiogenesis Inhibitor And Simulator Market

        • 6.3.8.1. Market Size and Forecast, By Product Type
        • 6.3.8.2. Market Size and Forecast, By End User

      • 6.3.9. UK Angiogenesis Inhibitor And Simulator Market

        • 6.3.9.1. Market Size and Forecast, By Product Type
        • 6.3.9.2. Market Size and Forecast, By End User

      • 6.3.10. Russia Angiogenesis Inhibitor And Simulator Market

        • 6.3.10.1. Market Size and Forecast, By Product Type
        • 6.3.10.2. Market Size and Forecast, By End User

      • 6.3.11. Rest Of Europe Angiogenesis Inhibitor And Simulator Market

        • 6.3.11.1. Market Size and Forecast, By Product Type
        • 6.3.11.2. Market Size and Forecast, By End User

    • 6.4. Asia-Pacific

      • 6.4.1. Key Market Trends and Opportunities

      • 6.4.2. Market Size and Forecast, By Product Type

      • 6.4.3. Market Size and Forecast, By End User

      • 6.4.4. Market Size and Forecast, By Country

      • 6.4.5. China Angiogenesis Inhibitor And Simulator Market

        • 6.4.5.1. Market Size and Forecast, By Product Type
        • 6.4.5.2. Market Size and Forecast, By End User

      • 6.4.6. Japan Angiogenesis Inhibitor And Simulator Market

        • 6.4.6.1. Market Size and Forecast, By Product Type
        • 6.4.6.2. Market Size and Forecast, By End User

      • 6.4.7. India Angiogenesis Inhibitor And Simulator Market

        • 6.4.7.1. Market Size and Forecast, By Product Type
        • 6.4.7.2. Market Size and Forecast, By End User

      • 6.4.8. South Korea Angiogenesis Inhibitor And Simulator Market

        • 6.4.8.1. Market Size and Forecast, By Product Type
        • 6.4.8.2. Market Size and Forecast, By End User

      • 6.4.9. Australia Angiogenesis Inhibitor And Simulator Market

        • 6.4.9.1. Market Size and Forecast, By Product Type
        • 6.4.9.2. Market Size and Forecast, By End User

      • 6.4.10. Thailand Angiogenesis Inhibitor And Simulator Market

        • 6.4.10.1. Market Size and Forecast, By Product Type
        • 6.4.10.2. Market Size and Forecast, By End User

      • 6.4.11. Malaysia Angiogenesis Inhibitor And Simulator Market

        • 6.4.11.1. Market Size and Forecast, By Product Type
        • 6.4.11.2. Market Size and Forecast, By End User

      • 6.4.12. Indonesia Angiogenesis Inhibitor And Simulator Market

        • 6.4.12.1. Market Size and Forecast, By Product Type
        • 6.4.12.2. Market Size and Forecast, By End User

      • 6.4.13. Rest of Asia Pacific Angiogenesis Inhibitor And Simulator Market

        • 6.4.13.1. Market Size and Forecast, By Product Type
        • 6.4.13.2. Market Size and Forecast, By End User

    • 6.5. LAMEA

      • 6.5.1. Key Market Trends and Opportunities

      • 6.5.2. Market Size and Forecast, By Product Type

      • 6.5.3. Market Size and Forecast, By End User

      • 6.5.4. Market Size and Forecast, By Country

      • 6.5.5. Brazil Angiogenesis Inhibitor And Simulator Market

        • 6.5.5.1. Market Size and Forecast, By Product Type
        • 6.5.5.2. Market Size and Forecast, By End User

      • 6.5.6. South Africa Angiogenesis Inhibitor And Simulator Market

        • 6.5.6.1. Market Size and Forecast, By Product Type
        • 6.5.6.2. Market Size and Forecast, By End User

      • 6.5.7. Saudi Arabia Angiogenesis Inhibitor And Simulator Market

        • 6.5.7.1. Market Size and Forecast, By Product Type
        • 6.5.7.2. Market Size and Forecast, By End User

      • 6.5.8. UAE Angiogenesis Inhibitor And Simulator Market

        • 6.5.8.1. Market Size and Forecast, By Product Type
        • 6.5.8.2. Market Size and Forecast, By End User

      • 6.5.9. Argentina Angiogenesis Inhibitor And Simulator Market

        • 6.5.9.1. Market Size and Forecast, By Product Type
        • 6.5.9.2. Market Size and Forecast, By End User

      • 6.5.10. Rest of LAMEA Angiogenesis Inhibitor And Simulator Market

        • 6.5.10.1. Market Size and Forecast, By Product Type
        • 6.5.10.2. Market Size and Forecast, By End User

  • CHAPTER 7: COMPETITIVE LANDSCAPE

    • 7.1. Introduction

    • 7.2. Top Winning Strategies

    • 7.3. Product Mapping Of Top 10 Player

    • 7.4. Competitive Dashboard

    • 7.5. Competitive Heatmap

    • 7.6. Top Player Positioning,2022

  • CHAPTER 8: COMPANY PROFILES

    • 8.1. F. Hoffmann-La Roche Ltd

      • 8.1.1. Company Overview

      • 8.1.2. Key Executives

      • 8.1.3. Company Snapshot

      • 8.1.4. Operating Business Segments

      • 8.1.5. Product Portfolio

      • 8.1.6. Business Performance

      • 8.1.7. Key Strategic Moves and Developments

    • 8.2. Abbott

      • 8.2.1. Company Overview

      • 8.2.2. Key Executives

      • 8.2.3. Company Snapshot

      • 8.2.4. Operating Business Segments

      • 8.2.5. Product Portfolio

      • 8.2.6. Business Performance

      • 8.2.7. Key Strategic Moves and Developments

    • 8.3. Bristol-Myers Squibb Company

      • 8.3.1. Company Overview

      • 8.3.2. Key Executives

      • 8.3.3. Company Snapshot

      • 8.3.4. Operating Business Segments

      • 8.3.5. Product Portfolio

      • 8.3.6. Business Performance

      • 8.3.7. Key Strategic Moves and Developments

    • 8.4. Amgen Inc.,

      • 8.4.1. Company Overview

      • 8.4.2. Key Executives

      • 8.4.3. Company Snapshot

      • 8.4.4. Operating Business Segments

      • 8.4.5. Product Portfolio

      • 8.4.6. Business Performance

      • 8.4.7. Key Strategic Moves and Developments

    • 8.5. AstraZeneca

      • 8.5.1. Company Overview

      • 8.5.2. Key Executives

      • 8.5.3. Company Snapshot

      • 8.5.4. Operating Business Segments

      • 8.5.5. Product Portfolio

      • 8.5.6. Business Performance

      • 8.5.7. Key Strategic Moves and Developments

    • 8.6. Novartis AG

      • 8.6.1. Company Overview

      • 8.6.2. Key Executives

      • 8.6.3. Company Snapshot

      • 8.6.4. Operating Business Segments

      • 8.6.5. Product Portfolio

      • 8.6.6. Business Performance

      • 8.6.7. Key Strategic Moves and Developments

    • 8.7. CASI Pharmaceuticals Inc.

      • 8.7.1. Company Overview

      • 8.7.2. Key Executives

      • 8.7.3. Company Snapshot

      • 8.7.4. Operating Business Segments

      • 8.7.5. Product Portfolio

      • 8.7.6. Business Performance

      • 8.7.7. Key Strategic Moves and Developments

    • 8.8. EYETECH DIGITAL SYSTEMS

      • 8.8.1. Company Overview

      • 8.8.2. Key Executives

      • 8.8.3. Company Snapshot

      • 8.8.4. Operating Business Segments

      • 8.8.5. Product Portfolio

      • 8.8.6. Business Performance

      • 8.8.7. Key Strategic Moves and Developments

    • 8.9. Johns Hopkins Medicine

      • 8.9.1. Company Overview

      • 8.9.2. Key Executives

      • 8.9.3. Company Snapshot

      • 8.9.4. Operating Business Segments

      • 8.9.5. Product Portfolio

      • 8.9.6. Business Performance

      • 8.9.7. Key Strategic Moves and Developments

    • 8.10. Pfizer Inc.

      • 8.10.1. Company Overview

      • 8.10.2. Key Executives

      • 8.10.3. Company Snapshot

      • 8.10.4. Operating Business Segments

      • 8.10.5. Product Portfolio

      • 8.10.6. Business Performance

      • 8.10.7. Key Strategic Moves and Developments

  • LIST OF TABLES

  • TABLE 1. GLOBAL ANGIOGENESIS INHIBITOR AND SIMULATOR MARKET, BY PRODUCT TYPE, 2022-2032 ($MILLION)
  • TABLE 2. GLOBAL ANGIOGENESIS INHIBITOR AND SIMULATOR MARKET FOR INTUSSUSCEPTIVE ANGIOGENESIS  , BY REGION, 2022-2032 ($MILLION)
  • TABLE 3. GLOBAL ANGIOGENESIS INHIBITOR AND SIMULATOR MARKET FOR SPROUTING ANGIOGENESIS, BY REGION, 2022-2032 ($MILLION)
  • TABLE 4. GLOBAL ANGIOGENESIS INHIBITOR AND SIMULATOR MARKET, BY END USER, 2022-2032 ($MILLION)
  • TABLE 5. GLOBAL ANGIOGENESIS INHIBITOR AND SIMULATOR MARKET FOR HOSPITALS, BY REGION, 2022-2032 ($MILLION)
  • TABLE 6. GLOBAL ANGIOGENESIS INHIBITOR AND SIMULATOR MARKET FOR CLINICS, BY REGION, 2022-2032 ($MILLION)
  • TABLE 7. GLOBAL ANGIOGENESIS INHIBITOR AND SIMULATOR MARKET FOR OTHERS, BY REGION, 2022-2032 ($MILLION)
  • TABLE 8. GLOBAL ANGIOGENESIS INHIBITOR AND SIMULATOR MARKET, BY REGION, 2022-2032 ($MILLION)
  • TABLE 9. NORTH AMERICA ANGIOGENESIS INHIBITOR AND SIMULATOR, BY REGION, 2022-2032 ($MILLION)
  • TABLE 10. NORTH AMERICA ANGIOGENESIS INHIBITOR AND SIMULATOR, BY PRODUCT TYPE, 2022-2032 ($MILLION)
  • TABLE 11. NORTH AMERICA ANGIOGENESIS INHIBITOR AND SIMULATOR, BY END USER, 2022-2032 ($MILLION)
  • TABLE 12. U.S. ANGIOGENESIS INHIBITOR AND SIMULATOR, BY PRODUCT TYPE, 2022-2032 ($MILLION)
  • TABLE 13. U.S. ANGIOGENESIS INHIBITOR AND SIMULATOR, BY END USER, 2022-2032 ($MILLION)
  • TABLE 14. CANADA ANGIOGENESIS INHIBITOR AND SIMULATOR, BY PRODUCT TYPE, 2022-2032 ($MILLION)
  • TABLE 15. CANADA ANGIOGENESIS INHIBITOR AND SIMULATOR, BY END USER, 2022-2032 ($MILLION)
  • TABLE 16. MEXICO ANGIOGENESIS INHIBITOR AND SIMULATOR, BY PRODUCT TYPE, 2022-2032 ($MILLION)
  • TABLE 17. MEXICO ANGIOGENESIS INHIBITOR AND SIMULATOR, BY END USER, 2022-2032 ($MILLION)
  • TABLE 18. EUROPE ANGIOGENESIS INHIBITOR AND SIMULATOR, BY REGION, 2022-2032 ($MILLION)
  • TABLE 19. EUROPE ANGIOGENESIS INHIBITOR AND SIMULATOR, BY PRODUCT TYPE, 2022-2032 ($MILLION)
  • TABLE 20. EUROPE ANGIOGENESIS INHIBITOR AND SIMULATOR, BY END USER, 2022-2032 ($MILLION)
  • TABLE 21. FRANCE ANGIOGENESIS INHIBITOR AND SIMULATOR, BY PRODUCT TYPE, 2022-2032 ($MILLION)
  • TABLE 22. FRANCE ANGIOGENESIS INHIBITOR AND SIMULATOR, BY END USER, 2022-2032 ($MILLION)
  • TABLE 23. GERMANY ANGIOGENESIS INHIBITOR AND SIMULATOR, BY PRODUCT TYPE, 2022-2032 ($MILLION)
  • TABLE 24. GERMANY ANGIOGENESIS INHIBITOR AND SIMULATOR, BY END USER, 2022-2032 ($MILLION)
  • TABLE 25. ITALY ANGIOGENESIS INHIBITOR AND SIMULATOR, BY PRODUCT TYPE, 2022-2032 ($MILLION)
  • TABLE 26. ITALY ANGIOGENESIS INHIBITOR AND SIMULATOR, BY END USER, 2022-2032 ($MILLION)
  • TABLE 27. SPAIN ANGIOGENESIS INHIBITOR AND SIMULATOR, BY PRODUCT TYPE, 2022-2032 ($MILLION)
  • TABLE 28. SPAIN ANGIOGENESIS INHIBITOR AND SIMULATOR, BY END USER, 2022-2032 ($MILLION)
  • TABLE 29. UK ANGIOGENESIS INHIBITOR AND SIMULATOR, BY PRODUCT TYPE, 2022-2032 ($MILLION)
  • TABLE 30. UK ANGIOGENESIS INHIBITOR AND SIMULATOR, BY END USER, 2022-2032 ($MILLION)
  • TABLE 31. RUSSIA ANGIOGENESIS INHIBITOR AND SIMULATOR, BY PRODUCT TYPE, 2022-2032 ($MILLION)
  • TABLE 32. RUSSIA ANGIOGENESIS INHIBITOR AND SIMULATOR, BY END USER, 2022-2032 ($MILLION)
  • TABLE 33. REST OF EUROPE ANGIOGENESIS INHIBITOR AND SIMULATOR, BY PRODUCT TYPE, 2022-2032 ($MILLION)
  • TABLE 34. REST OF EUROPE ANGIOGENESIS INHIBITOR AND SIMULATOR, BY END USER, 2022-2032 ($MILLION)
  • TABLE 35. ASIA-PACIFIC ANGIOGENESIS INHIBITOR AND SIMULATOR, BY REGION, 2022-2032 ($MILLION)
  • TABLE 36. ASIA-PACIFIC ANGIOGENESIS INHIBITOR AND SIMULATOR, BY PRODUCT TYPE, 2022-2032 ($MILLION)
  • TABLE 37. ASIA-PACIFIC ANGIOGENESIS INHIBITOR AND SIMULATOR, BY END USER, 2022-2032 ($MILLION)
  • TABLE 38. CHINA ANGIOGENESIS INHIBITOR AND SIMULATOR, BY PRODUCT TYPE, 2022-2032 ($MILLION)
  • TABLE 39. CHINA ANGIOGENESIS INHIBITOR AND SIMULATOR, BY END USER, 2022-2032 ($MILLION)
  • TABLE 40. JAPAN ANGIOGENESIS INHIBITOR AND SIMULATOR, BY PRODUCT TYPE, 2022-2032 ($MILLION)
  • TABLE 41. JAPAN ANGIOGENESIS INHIBITOR AND SIMULATOR, BY END USER, 2022-2032 ($MILLION)
  • TABLE 42. INDIA ANGIOGENESIS INHIBITOR AND SIMULATOR, BY PRODUCT TYPE, 2022-2032 ($MILLION)
  • TABLE 43. INDIA ANGIOGENESIS INHIBITOR AND SIMULATOR, BY END USER, 2022-2032 ($MILLION)
  • TABLE 44. SOUTH KOREA ANGIOGENESIS INHIBITOR AND SIMULATOR, BY PRODUCT TYPE, 2022-2032 ($MILLION)
  • TABLE 45. SOUTH KOREA ANGIOGENESIS INHIBITOR AND SIMULATOR, BY END USER, 2022-2032 ($MILLION)
  • TABLE 46. AUSTRALIA ANGIOGENESIS INHIBITOR AND SIMULATOR, BY PRODUCT TYPE, 2022-2032 ($MILLION)
  • TABLE 47. AUSTRALIA ANGIOGENESIS INHIBITOR AND SIMULATOR, BY END USER, 2022-2032 ($MILLION)
  • TABLE 48. THAILAND ANGIOGENESIS INHIBITOR AND SIMULATOR, BY PRODUCT TYPE, 2022-2032 ($MILLION)
  • TABLE 49. THAILAND ANGIOGENESIS INHIBITOR AND SIMULATOR, BY END USER, 2022-2032 ($MILLION)
  • TABLE 50. MALAYSIA ANGIOGENESIS INHIBITOR AND SIMULATOR, BY PRODUCT TYPE, 2022-2032 ($MILLION)
  • TABLE 51. MALAYSIA ANGIOGENESIS INHIBITOR AND SIMULATOR, BY END USER, 2022-2032 ($MILLION)
  • TABLE 52. INDONESIA ANGIOGENESIS INHIBITOR AND SIMULATOR, BY PRODUCT TYPE, 2022-2032 ($MILLION)
  • TABLE 53. INDONESIA ANGIOGENESIS INHIBITOR AND SIMULATOR, BY END USER, 2022-2032 ($MILLION)
  • TABLE 54. REST OF ASIA PACIFIC ANGIOGENESIS INHIBITOR AND SIMULATOR, BY PRODUCT TYPE, 2022-2032 ($MILLION)
  • TABLE 55. REST OF ASIA PACIFIC ANGIOGENESIS INHIBITOR AND SIMULATOR, BY END USER, 2022-2032 ($MILLION)
  • TABLE 56. LAMEA ANGIOGENESIS INHIBITOR AND SIMULATOR, BY REGION, 2022-2032 ($MILLION)
  • TABLE 57. LAMEA ANGIOGENESIS INHIBITOR AND SIMULATOR, BY PRODUCT TYPE, 2022-2032 ($MILLION)
  • TABLE 58. LAMEA ANGIOGENESIS INHIBITOR AND SIMULATOR, BY END USER, 2022-2032 ($MILLION)
  • TABLE 59. BRAZIL ANGIOGENESIS INHIBITOR AND SIMULATOR, BY PRODUCT TYPE, 2022-2032 ($MILLION)
  • TABLE 60. BRAZIL ANGIOGENESIS INHIBITOR AND SIMULATOR, BY END USER, 2022-2032 ($MILLION)
  • TABLE 61. SOUTH AFRICA ANGIOGENESIS INHIBITOR AND SIMULATOR, BY PRODUCT TYPE, 2022-2032 ($MILLION)
  • TABLE 62. SOUTH AFRICA ANGIOGENESIS INHIBITOR AND SIMULATOR, BY END USER, 2022-2032 ($MILLION)
  • TABLE 63. SAUDI ARABIA ANGIOGENESIS INHIBITOR AND SIMULATOR, BY PRODUCT TYPE, 2022-2032 ($MILLION)
  • TABLE 64. SAUDI ARABIA ANGIOGENESIS INHIBITOR AND SIMULATOR, BY END USER, 2022-2032 ($MILLION)
  • TABLE 65. UAE ANGIOGENESIS INHIBITOR AND SIMULATOR, BY PRODUCT TYPE, 2022-2032 ($MILLION)
  • TABLE 66. UAE ANGIOGENESIS INHIBITOR AND SIMULATOR, BY END USER, 2022-2032 ($MILLION)
  • TABLE 67. ARGENTINA ANGIOGENESIS INHIBITOR AND SIMULATOR, BY PRODUCT TYPE, 2022-2032 ($MILLION)
  • TABLE 68. ARGENTINA ANGIOGENESIS INHIBITOR AND SIMULATOR, BY END USER, 2022-2032 ($MILLION)
  • TABLE 69. REST OF LAMEA ANGIOGENESIS INHIBITOR AND SIMULATOR, BY PRODUCT TYPE, 2022-2032 ($MILLION)
  • TABLE 70. REST OF LAMEA ANGIOGENESIS INHIBITOR AND SIMULATOR, BY END USER, 2022-2032 ($MILLION)
  • TABLE 71. F. HOFFMANN-LA ROCHE LTD: KEY EXECUTIVES
  • TABLE 72. F. HOFFMANN-LA ROCHE LTD: COMPANY SNAPSHOT
  • TABLE 73. F. HOFFMANN-LA ROCHE LTD: OPERATING SEGMENTS
  • TABLE 74. F. HOFFMANN-LA ROCHE LTD: PRODUCT PORTFOLIO
  • TABLE 75. F. HOFFMANN-LA ROCHE LTD: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 76. ABBOTT: KEY EXECUTIVES
  • TABLE 77. ABBOTT: COMPANY SNAPSHOT
  • TABLE 78. ABBOTT: OPERATING SEGMENTS
  • TABLE 79. ABBOTT: PRODUCT PORTFOLIO
  • TABLE 80. ABBOTT: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 81. BRISTOL-MYERS SQUIBB COMPANY: KEY EXECUTIVES
  • TABLE 82. BRISTOL-MYERS SQUIBB COMPANY: COMPANY SNAPSHOT
  • TABLE 83. BRISTOL-MYERS SQUIBB COMPANY: OPERATING SEGMENTS
  • TABLE 84. BRISTOL-MYERS SQUIBB COMPANY: PRODUCT PORTFOLIO
  • TABLE 85. BRISTOL-MYERS SQUIBB COMPANY: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 86. AMGEN INC.,: KEY EXECUTIVES
  • TABLE 87. AMGEN INC.,: COMPANY SNAPSHOT
  • TABLE 88. AMGEN INC.,: OPERATING SEGMENTS
  • TABLE 89. AMGEN INC.,: PRODUCT PORTFOLIO
  • TABLE 90. AMGEN INC.,: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 91. ASTRAZENECA: KEY EXECUTIVES
  • TABLE 92. ASTRAZENECA: COMPANY SNAPSHOT
  • TABLE 93. ASTRAZENECA: OPERATING SEGMENTS
  • TABLE 94. ASTRAZENECA: PRODUCT PORTFOLIO
  • TABLE 95. ASTRAZENECA: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 96. NOVARTIS AG: KEY EXECUTIVES
  • TABLE 97. NOVARTIS AG: COMPANY SNAPSHOT
  • TABLE 98. NOVARTIS AG: OPERATING SEGMENTS
  • TABLE 99. NOVARTIS AG: PRODUCT PORTFOLIO
  • TABLE 100. NOVARTIS AG: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 101. CASI PHARMACEUTICALS INC.: KEY EXECUTIVES
  • TABLE 102. CASI PHARMACEUTICALS INC.: COMPANY SNAPSHOT
  • TABLE 103. CASI PHARMACEUTICALS INC.: OPERATING SEGMENTS
  • TABLE 104. CASI PHARMACEUTICALS INC.: PRODUCT PORTFOLIO
  • TABLE 105. CASI PHARMACEUTICALS INC.: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 106. EYETECH DIGITAL SYSTEMS: KEY EXECUTIVES
  • TABLE 107. EYETECH DIGITAL SYSTEMS: COMPANY SNAPSHOT
  • TABLE 108. EYETECH DIGITAL SYSTEMS: OPERATING SEGMENTS
  • TABLE 109. EYETECH DIGITAL SYSTEMS: PRODUCT PORTFOLIO
  • TABLE 110. EYETECH DIGITAL SYSTEMS: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 111. JOHNS HOPKINS MEDICINE: KEY EXECUTIVES
  • TABLE 112. JOHNS HOPKINS MEDICINE: COMPANY SNAPSHOT
  • TABLE 113. JOHNS HOPKINS MEDICINE: OPERATING SEGMENTS
  • TABLE 114. JOHNS HOPKINS MEDICINE: PRODUCT PORTFOLIO
  • TABLE 115. JOHNS HOPKINS MEDICINE: KEY STRATEGIC MOVES AND DEVELOPMENTS
  • TABLE 116. PFIZER INC.: KEY EXECUTIVES
  • TABLE 117. PFIZER INC.: COMPANY SNAPSHOT
  • TABLE 118. PFIZER INC.: OPERATING SEGMENTS
  • TABLE 119. PFIZER INC.: PRODUCT PORTFOLIO
  • TABLE 120. PFIZER INC.: KEY STRATEGIC MOVES AND DEVELOPMENTS

  • LIST OF FIGURES

  • FIGURE 1. GLOBAL ANGIOGENESIS INHIBITOR AND SIMULATOR MARKET SEGMENTATION
  • FIGURE 2. GLOBAL ANGIOGENESIS INHIBITOR AND SIMULATOR MARKET
  • FIGURE 3. SEGMENTATION ANGIOGENESIS INHIBITOR AND SIMULATOR MARKET
  • FIGURE 4. TOP INVESTMENT POCKET IN ANGIOGENESIS INHIBITOR AND SIMULATOR MARKET
  • FIGURE 5. MODERATE BARGAINING POWER OF BUYERS
  • FIGURE 6. MODERATE BARGAINING POWER OF SUPPLIERS
  • FIGURE 7. MODERATE THREAT OF NEW ENTRANTS
  • FIGURE 8. LOW THREAT OF SUBSTITUTION
  • FIGURE 9. HIGH COMPETITIVE RIVALRY
  • FIGURE 10. OPPORTUNITIES, RESTRAINTS AND DRIVERS: GLOBALANGIOGENESIS INHIBITOR AND SIMULATOR MARKET
  • FIGURE 11. ANGIOGENESIS INHIBITOR AND SIMULATOR MARKET SEGMENTATION, BY BY PRODUCT TYPE
  • FIGURE 12. ANGIOGENESIS INHIBITOR AND SIMULATOR MARKET FOR INTUSSUSCEPTIVE ANGIOGENESIS  , BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 13. ANGIOGENESIS INHIBITOR AND SIMULATOR MARKET FOR SPROUTING ANGIOGENESIS, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 14. ANGIOGENESIS INHIBITOR AND SIMULATOR MARKET SEGMENTATION, BY BY END USER
  • FIGURE 15. ANGIOGENESIS INHIBITOR AND SIMULATOR MARKET FOR HOSPITALS, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 16. ANGIOGENESIS INHIBITOR AND SIMULATOR MARKET FOR CLINICS, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 17. ANGIOGENESIS INHIBITOR AND SIMULATOR MARKET FOR OTHERS, BY COUNTRY, 2022-2032 ($MILLION)
  • FIGURE 18. TOP WINNING STRATEGIES, BY YEAR, 2020-2022*
  • FIGURE 19. TOP WINNING STRATEGIES, BY DEVELOPMENT, 2020-2022*
  • FIGURE 20. TOP WINNING STRATEGIES, BY COMPANY, 2020-2022*
  • FIGURE 21. PRODUCT MAPPING OF TOP 10 PLAYERS
  • FIGURE 22. COMPETITIVE DASHBOARD
  • FIGURE 23. COMPETITIVE HEATMAP: ANGIOGENESIS INHIBITOR AND SIMULATOR MARKET
  • FIGURE 24. Top player positioning, 2022
  • FIGURE 25. F. HOFFMANN-LA ROCHE LTD: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 26. F. HOFFMANN-LA ROCHE LTD: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 27. F. HOFFMANN-LA ROCHE LTD: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 28. ABBOTT: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 29. ABBOTT: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 30. ABBOTT: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 31. BRISTOL-MYERS SQUIBB COMPANY: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 32. BRISTOL-MYERS SQUIBB COMPANY: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 33. BRISTOL-MYERS SQUIBB COMPANY: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 34. AMGEN INC.,: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 35. AMGEN INC.,: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 36. AMGEN INC.,: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 37. ASTRAZENECA: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 38. ASTRAZENECA: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 39. ASTRAZENECA: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 40. NOVARTIS AG: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 41. NOVARTIS AG: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 42. NOVARTIS AG: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 43. CASI PHARMACEUTICALS INC.: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 44. CASI PHARMACEUTICALS INC.: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 45. CASI PHARMACEUTICALS INC.: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 46. EYETECH DIGITAL SYSTEMS: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 47. EYETECH DIGITAL SYSTEMS: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 48. EYETECH DIGITAL SYSTEMS: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 49. JOHNS HOPKINS MEDICINE: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 50. JOHNS HOPKINS MEDICINE: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 51. JOHNS HOPKINS MEDICINE: REVENUE SHARE, BY REGION, 2032 (%)
  • FIGURE 52. PFIZER INC.: NET SALES, 2020-2022 ($MILLION)
  • FIGURE 53. PFIZER INC.: REVENUE SHARE, BY SEGMENT, 2032 (%)
  • FIGURE 54. PFIZER INC.: REVENUE SHARE, BY REGION, 2032 (%)

 
 
With collective industry experience of about 200 years of its analysts and experts, Allied Market Research (AMR) encompasses most infallible research methodology for its market intelligence and industry analysis. We do not only engrave the deepest levels of markets but also sneak through its slimmest details for the purpose of our market estimates and forecasts. Our approach helps in building greater market consensus view for size, shape and industry trends within each industry segment. We carefully factor in industry trends and real developments for identifying key growth factors and future course of the market. Our research proceeds are the resultant of high quality data, expert views and analysis and high value independent opinions. Our research process is designed to deliver balanced view of the global markets and allow stakeholders to make informed decisions.

We offer our clients exhaustive research and analysis based on wide variety of factual inputs, which largely include interviews with industry participants, reliable statistics and regional intelligence. Our in-house industry experts play instrumental role in designing analytic tools and models, tailored to the requirements of particular industry segment. These analytical tools and models sanitize the data & statistics and enhance the accuracy of our recommendations and advice. With AMR’s calibrated research process and 360` degree data-evaluation methodology, our clients are assured of receiving:

  • Consistent, valuable, robust and actionable data & analysis that can easily be referenced for strategic business planning
  • Technologically sophisticated and reliable insights through well audited and veracious research methodology
  • Sovereign research proceeds that present a tangible depiction of marketplace


With a strong methodology we are, therefore, confident that our research and analysis are most reliable and guarantees sound business planning.

Secondary research
We refer a broad array of industry sources for our secondary, which typically include; however, not limited to: Company SEC filings, annual reports, company websites, broker & financial reports and investor presentations for competitive scenario and shape of the industry

  • Patent and regulatory databases for understanding of technical & legal developments
  • Scientific and technical writings for product information and related preemptions
  • Regional government and statistical databases for macro analysis
  • Authentic new articles, web-casts and other related releases for market evaluation
  • Internal and external proprietary databases, key market indicators and relevant press releases for market estimates and forecast


Primary research
Our primary research efforts include reaching out participants through mail, tele-conversations, referrals, professional networks and face-to-face interactions. We are also in professional corporate relations with various companies that allow us greater flexibility for reaching out industry participants and commentators for interviews and discussions, fulfilling following functions:

  • Validates and improves the data quality and strengthens research proceeds
  • Further develops analyst team’s market understanding and expertise
  • Supplies authentic information about market size, share, growth and forecasts


Our primary research interview and discussion panels are typically composed of most experienced industry members. These participants include; however, not limited to:

  • Chief executives and VPs of leading corporations specific to industry
  • Product and sales managers or country heads; channel partners and top level distributors; banking, investments and valuation experts Key opinion leaders (KOLs)


Analyst tools and models
AMR has developed set of analyst tools and data models to supplement and expedite the analysis process. Corresponding to markets, where there is significant lack of information and estimates, AMR’s team of experts and analyst develop specific analyst tools and industry models to translate qualitative and quantitative industry indicators into exact industry estimates. These models also allow analysts to examine the prospects and opportunities prevailing in the market to accurately forecast the course of the market.

PURCHASE OPTIONS

Call or Email us

U.S.-Canada Toll-free: +1-800-792-5285
Int'l : +1-503-894-6022
Europe : +44-845-528-1300
Email : help@alliedmarketresearch.com

Looking for Customization?

 Customization Request

Have a Question?

 Speak with Analyst

Any Confusion?

 Inquire Before Buying

Have a glance of the Report

  Enquiry Now
RELATED TAGS

Purchase Full Report of
Angiogenesis Inhibitor And Simulator Market

Start reading.
This Report and over 66,944+ more Reports, Available with Avenue Library. T&C*.

  • Online Only
  • $3,690
  • Online cloud access only
  • Restricted print, copy, paste & download
  • Read only
  • Free industry update
    (Within 180 days)
  • Free report update in next update cycle
  • Data Pack
  • $3,930
  • Restricted to one authorized user
  • One print only
  • Available in
    Excel
  • Free industry update
    (Within 180 days)
  •   Free report update in next update cycle
  • Single User
  • $5,820
  • Restricted to one authorized user
  • One print only
  • Available in
    PDF
  • Free industry update
    (Within 180 days)
  •   Free report update in next update cycle
  • Five Users
  • $6,540
  • Limited to five authorized users
  • Print upto five copies
  • Available in
    PDF
  • Free industry update
    (Within 180 days)
  •   Free report update in next update cycle

  • Enterprise
    License/PDF

  • $9,870
  • Unlimited
    within
    company/enterprise
  • Available in Excel & PDF
  • Free industry update
    (Within 180 days)
  •   Free report update in next update cycle

  • Library
    Membership

  • $999 $ 1,175
    Per User/ Per month/ Billed annually
  • Published Content
    E-access
  • Company Profiles
    E-access
  • Newly Added Content Access
  • 10 PDF
    Downloads
  • 5 Excel Data
    Pack Downloads
  • 250 Company Profiles PDF Downloads
  • Buy Now

*Taxes/Fees, if applicable will be added during checkout. All prices in USD

RELATED REPORTS
 

Why Allied Market Research?

 

Infallible Methodology

To ensure high-level data integrity, accurate analysis, and impeccable forecasts

Analyst Support

For complete satisfaction

Customization

On-demand customization of scope of the report to exactly meet your needs

TARGETED MARKET VIEW

Targeted market view to provide pertinent information and save time of readers

Get fresh content delivered

Get insights on topics that are crucial for your business. Stay abreast of your interest areas.

Get Industry Data Alerts

Why Allied Market Research?

Infallible Methodology

To ensure high-level data integrity, accurate analysis, and impeccable forecasts

Analyst Support

For complete satisfaction

Customization

On-demand customization of scope of the report to exactly meet your needs

TARGETED MARKET VIEW

Targeted market view to provide pertinent information and save time of readers